About Hoth Therapeutics, Inc. - Common Stock (HOTH)
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for various dermatological conditions and related diseases. The company leverages its proprietary drug delivery systems and advanced therapeutics to address unmet medical needs, particularly in the treatment of skin disorders such as atopic dermatitis and psoriasis. Hoth's research is centered on bringing new solutions to patients by improving the efficacy and safety of existing treatments, thus enhancing the quality of life for those affected by challenging skin conditions. Read More
Biotech is once again capturing investor attention, with small-cap companies in particular drawing focus for their potential to deliver breakthrough therapies and regulatory milestones. Over the past six months, clinical-stage biotechs reporting meaningful data have moved an average of nearly 12 percent in a single day, showing how quickly the market reacts to progress. With multiple programs across oncology, supportive care, and metabolic disease advancing toward key readouts, the sector is generating a steady stream of opportunities for investors seeking high-impact growth. In this environment, emerging companies with robust pipelines are worth watching closely.
NEW YORK - June 25th, 2025 - Silo Pharma, Inc. ( Nasdaq: SILO ) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University.
SILO Pharma (NASDAQ: SILO) today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease.
Hoth Therapeutics (NASDAQ: HOTH) is at the forefront of developing innovative therapies for unmet medical needs. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
